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In silico physiologically-based 
pharmacokinetic modeling 
a b s t r a c t 
This study aims to understand the absorption patterns of three different kinds of 
inhaled formulations via in silico modeling using budesonide (BUD) as a model drug. 
The formulations investigated in this study are: (i) commercially available micronized 
BUD mixed with lactose (BUD-PT), (ii) BUD nanocrystal suspension (BUD-NC), (iii) BUD 
nanocrystals embedded hyaluronic acid microparticles (BUD-NEM). The deposition patterns 
of the three inhaled formulations in the rats’ lungs were determined in vivo and in 
silico predicted, which were used as inputs in GastroPlus TM software to predict drug 
absorption following aerosolization of the tested formulations. BUD pharmacokinetics, 
estimated based on intravenous data in rats, was used to establish a drug-specific in 
silico absorption model. The BUD-specific in silico model revealed that drug pulmonary 
solubility and absorption rate constant were the key factors affecting pulmonary absorption 
of BUD-NC and BUD-NEM, respectively. In the case of BUD-PT, the in silico model revealed 
significant gastrointestinal absorption of BUD, which could be overlooked by traditional in 
vivo experimental observation. This study demonstrated that in vitro-in vivo-in silico approach 
was able to identify the key factors that influence the absorption of different inhaled 
formulations, which may facilitate the development of orally inhaled formulations with 
different drug release/absorption rates. 
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Novel trends in drug discovery and formulation
development impose the use of in silico physiologically-
based pharmacokinetic (PBPK) modeling tools to estimate
drug pharmacokinetic and pharmacodynamic properties.
A number of examples regarding modeling of drug
bioperformance are available in literature, however they
mostly concern peroral drug administration [1–5] . On the
other hand, advanced in silico models aimed to simulate
absorption and disposition of drugs dosed by alternative
routes, including pulmonary administration, appeared more
recently. Up to date, only a few publications have described the
use of in silico tools for modeling inhaled drugs performance
[6–12] . PBPK modeling of inhaled drugs requires a number of
input data, and the selection of such dataset is a laborious
task. Moreover, the available models are currently in the early
developmental phase, and still not able to simulate all the
processes that may affect drugs’ disposition in the lungs.
However, they have a high potential to facilitate development
of inhaled drug products, especially in combination with
preclinical animal studies. Jones et al . [13] have proposed an
in vivo-in silico strategy that involves modeling across species
to estimate drug performance in humans. Although initially
proposed for oral drugs, such an approach could also be
applied for inhaled drugs, whereas the first step would be to
construct and validate an in silico animal ( e.g., rat) model for
intratracheally administered drugs. 
In silico modeling of pulmonary drug delivery in
experimental animals is challenging because none of the
commercially available software is able to predict both drug
deposition and absorption in animal lungs. To exemplify,
PBPK software for the prediction of drug absorption ( e.g.,
GastroPlus TM , Mimetikos Preludium TM ) have built-in models
to estimate regional drug deposition and absorption in human
lungs, but not in animals e.g., rat respiratory tract. On the other
hand, respiratory tract dosimetry models, such as Multiple-
Path Particle Dosimetry (MPPD) model, are able to predict
deposition of aerosols in some animal species ( e.g., mouse,
rat, rabbit, rhesus monkey, pig), but the concomitant output
data regarding drug deposition cannot be used as raw inputs
in other software like GastroPlus TM to predict pulmonary
drug absorption. This discrepancy is caused by intrinsic
differences in the sub-regions of the lungs between MPPD
and GastroPlus TM software. Namely, MPPD model provides
data on the deposited fractions of drug in two pulmonary
regions (tracheobronchial and pulmonary/alveolar) while
GastroPlus TM requires data on drug deposition in four distinct
regions (extra-thoracic, thoracic, bronchiolar and alveolar),
and considers that partial or total fraction of deposited drug
in extra-thoracic region can be swallowed. 
In this study we attempted to establish the in silico rat
model for three intratracheally administered formulations
using budesonide (BUD) as a model drug ( Scheme 1 ). The
three inhaled formulations consisted of (i) commercially
available micronized BUD (Pulmicort R ©) mixed with coarse
lactose as a carrier (BUD-PT), (ii) BUD nanocrystal suspension
(BUD-NC), and (iii) BUD nanocrystals embedded hyaluronic
acid microparticles (BUD-NEM). The latter two formulationswere intended to render faster and slower (respectively) drug
absorption/dissolution rate in the rat lung than Pulmicort R ©
powder blended with lactose. The particle deposition data
of these three formulations in rats’ lungs were obtained
experimentally and used as input parameters in GastroPlus TM
in order to construct the BUD-specific in silico absorption rat
model. For comparison to the in vivo deposition data, BUD
deposition in rat lungs was predicted by MPPD software
and the obtained results were converted to GastroPlus TM
identifiable data, as described in the Supplementary
Data Appendix A. Finally, the drug absorption patterns
following intratracheal administration of the three inhaled
formulations were predicted and analyzed using the designed
model. 
2. Materials and methods 
2.1. Materials 
Budesonide (BUD) was purchased from Gedian Humanwell
Pharmaceutical Co. Ltd. (Hubei, China). Hyaluronic acid (HA)
was supplied by Shandong Freda Biotechnology Co. Ltd.
(Jinan, China). Pluronic F-68 (F68) was kindly provided by
BASF (China) Co. Ltd. Pulmicort Turbuhaler TM (AstraZeneca
AB, Sodertalje, Sweden) was purchased from a local pharmacy.
Sieved inhalation lactose in crystalline lactose grade
(Respitose R © SV003) was donated by DFE Pharma (Shanghai,
China). Purified water was produced using a Milli-Q R © plus
Millipore system (Millipore, Billerica, MA, USA). All other
chemicals were of analytical grade. 
2.2. Preparation of inhaled BUD formulations 
We previously reported in the study by Liu et al . [14] the
preparation of three inhaled formulations i.e., (i) BUD-PT, (ii)
BUD-NC, and (iii) BUD-NEM. In brief, BUD-PT was prepared
by blending the BUD powder collected from Pulmicort
Turbuhaler TM with inhalation lactose (Respitose R © SV003) at
a ratio of 1:4 (w/w) using a vortex mixer (Lab Dancer, IKA,
Germany) for 10 min. The obtained mixture was collected in
a closed glass vial and stored in a vacuum oven (DZF-6050,
Boxun, China) at room temperature for further use. This was
done to increase the bulk volume of the dry powder to suit
the application of Penn-Century dry powder insufflator ( i.e.,
1–5 mg). 
BUD-NC was prepared by mixing 1 g of BUD raw material
and 100 g zirconium oxide beads (0.5 mm in diameter) in
10 ml of 1% (w/v) F68 solution, followed by a milling process.
The milling was performed at a rotation speed of 500 rpm
for 120 min in a milling bowl equipped with a Pulverisette
7 Premium planetary ball mill (Fritsch GmbH, Germany).
Thereafter, milling cycles of 5-min run with 2-min pause were
applied to prevent overheating of the suspension and the
mill. At the end of the milling process, the suspension was
cooled down to room temperature and washed with purified
water three times to remove F68. Finally, the washed BUD
particles were resuspended in distilled water to give a final
concentration of 30 mg/ml. 
To prepare BUD-NEM, a liquid formulation composed of
0.1% (w/v) BUD-NC and 0.3% (w/v) HA solution was processed
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sing a laboratory scale Mini Spray Dryer Büchi B-290 (Büchi 
abortechnik AG, Switzerland) equipped with a 2-fluid nozzle 
ith an orifice diameter of 0.7 mm. The following process 
arameters were used i.e., the feeding rate of 4.5 ml/min, the 
spirator gas flow rate of 35 m 3 /h, the atomizing air flow rate 
f 437 l/h and the inlet temperature of 150 °C. The obtained 
UD-NEM dry powder was collected in a closed glass container 
nd stored in a vacuum oven (DZF-6050, Boxun, China) at room 
emperature for further use. 
.3. Aerodynamic particle size of aerosolized BUD 
owders 
he aerodynamic performance of BUD-NEM was assessed and 
eported in previously published paper [14] . In this study, the 
erodynamic properties of BUD-PT were evaluated using a 
ext generation impactor (NGI, Copley Scientific, Nottingham,
K). To minimize bouncing or re-entrainment of the particles,
ll cups of NGI were coated with 10% (v/v) Tween 20 solution in 
thanol. 10 mg of BUD-PT was filled into size 3 hypromellose 
apsules (Capsugel Co., Ltd, Suzhou, China) and inserted into 
 Cyclohaler R © dry powder inhaler (DPI) (Pharmachemie B.V.,
etherlands). Each capsule was aerosolized at a constant air 
ow rate of 100 l/min for an actuation time of 2.4 sec, and 
he assay was done in triplicate. After the aerosol settled,
he powder retained in the capsule, inhaler, adaptor, throat,
re-separator and all NGI stages were collected using an 
ppropriate volume of acetonitrile-water mixture 70:30 (v/v),
nd the drug content was determined by HPLC [14] . The ass median aerodynamic diameter (MMAD) and geometric 
tandard deviation (GSD) were calculated to characterize the 
n vitro particles deposition profile. 
.4. Droplets size of aerosolized BUD-NC 
he diameter of the aerosolized BUD-NC droplets was 
easured by a laser diffraction method using Malvern 
praytec R © (Malvern Panalytical Ltd, UK) equipped with RT 
izer software 3.20. In brief, 50 μl of BUD-NC was aerosolized 
nto fine droplets using a MicroSprayer R © Aerosolizer (Model 
A-1C, Penn-Century. Inc. Wyndmoor, PA) that was employed 
o intratracheally administer BUD-NC liquid aerosol in the 
at study described in the latter section. The aerosolized 
roplets that crossed the laser beam of Malvern Spraytec R ©
ere detected by the laser receptor, and the photoelectric 
ignals were converted into the information on particle size 
istribution by RT Sizer software. 
.5. Geometric particle size 
eometric particle sizes of the inhaled BUD formulations were 
sed to in silico simulate drug dissolution from the inhaled 
UD formulations in the animal lungs. 
The geometric particle sizes of BUD-NC and BUD-NEM 
ere taken from previously published paper [14] . The 
eometric particle size of BUD from BUD-PT was determined 
sing scanning electron microscopy (SEM) images. Briefly,
ore than 10 pictures for a sample were taken at randomly 




































































































selected sites, and then ImageJ (Version 1.51, National
Institutes of Health, USA) freeware was used to process the
SEM images through the following steps. Firstly, the SEM
pictures were loaded into the software, followed by setting
of the scale (of the known distance) versus unit pixels on the
picture. In the next step, a diagonal line was constructed to
distinguish the “objects” from numerous particles, and area of
each particle on the diagonal line was calculated. These values
were used to calculate the diameters of particles, based on the
assumption that each particle is a perfect circle. The result,
expressed as d 50 , was used as input parameter to simulate
drug dissolution. 
2.6. In vivo assessment of particles deposition patterns in
the rats lung 
The deposition patterns of the three inhaled BUD
formulations were reported in previous paper [15] . In
brief, BUD-PT, BUD-NC and BUD-NEM were intratracheally
administered to rats, then the animals’ respiratory organs
were isolated by surgical resection and divided into six
physiological parts: trachea, bronchi, bronchiole (left),
bronchiole (right), alveoli (left), and alveoli (right). After
the drug extraction from the lung tissues, the amount of BUD
in each of lungs’ six parts was measured using HPLC assay.
Finally, BUD deposition in the rats’ lungs compartments was
reported as a percentage of the total deposited dose. 
2.7. In vivo pharmacokinetic study 
The procedures were designed as reported in previously
published paper [14] , including the dosing method,
preparation of the plasma samples, and the HPLC
methodology for BUD quantification. Even though
pharmacokinetic studies on the three inhaled BUD
formulations have already been performed and reported,
a quick drug absorption from BUD-NC observed in the
previous study proposed us to redesign an earlier sampling
point i.e., 2-min to obtain a representative pharmacokinetic
profile. 
All animal research work reported in this article had been
carried out strictly in accordance with the guidelines from
the Life Science Research Center and Ethical Committee, and
all animal study protocols were agreed and signed by the
Institutional Animal Care and Use Committee (IACUC) at
Shenyang Pharmaceutical University at Liaoning (license NO.
SYPU-IACUC-C-2018–71–203) before the start of the animal
experiments. Animal welfare was strictly guaranteed, and
appropriate efforts were made to minimize animal sufferings
and to limit the number of animals used. All animals were
euthanized by anesthesia (diethyl ether) after completing the
experiments. 
2.7.1. Animals and husbandry 
Twenty male Sprague–Dawley rats (SD rats, 200–220 g body
weight, 10–12 weeks old) were supplied by the Experimental
Animal Center of Shenyang Pharmaceutical University
(Shenyang, China), and animal quality certificate was issued
by Liaoning Changsheng Biotechnology Co., Ltd. All rats were
randomly subdivided into 4 groups, that were a intravenous(IV) group ( n = 5), BUD-PT group ( n = 5), BUD-NC group ( n = 5)
and BUD-NEM group ( n = 5). Animals were acclimated for
at least 2 d prior to experiments and bred by free access
to food and water in breeding cages at about 25 °C, fasted
overnight (12 h) before dosing, and water was available ad
libitum throughout the study. 
2.7.2. Dosing formulations 
The administered dose was 0.2 mg BUD per 100 g rat
body weight. Briefly, pharmacokinetic study of intravenous
administration in the IV group was conducted by injecting
BUD solution (0.4 mg/ml) through rats’ tail vein. BUD-
PT and BUD-NEM were administered by a Dry Powder
Insufflator TM (DP-4-R, Penn-Century, Inc., Wyndmoor, PA, USA)
to deliver the preloaded powder to the rats’ airways. BUD-
NC suspension was directly aerosolized inside the trachea
with the MicroSprayer R © Aerosolizer. Subsequently, the blood
samples (0.2-ml at each time point) were collected into
heparin-coated centrifuge tubes from rats’ orbital venous
plexus at pre-determined time intervals 0 min, 2 min, 5 min,
15 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h and
24 h. Collected blood samples were immediately centrifuged
at 13,800 g for 5 min at 4 °C to obtain plasma which then was
stored at −20 °C until analysis. 
2.7.3. Sample extraction 
Prior to analyses, plasma samples were thawed at room
temperature. Plasma samples (100 μl) were then aliquoted
in 1.5 ml Eppendorf tubes, followed by mixing with 40 μl
of phosphoric acid solution (pH 3.2) and 10 μl of internal
standard-triamcinolon acetonide (4 μg/ml) for 1 min. To
extract BUD from the plasma samples, 1 ml of ethyl acetate
was added into the Eppendorf tubes, followed by vortex
mixing for 3 min, and centrifugation at 13,800 g for 5 min
at 4 °C. Then the organic phases were transferred to
Eppendorf tubes and the organic solvent was removed using a
concentrator under a nitrogen blowing at 40 °C. Subsequently,
100 μl of mobile phase was added to Eppendorf tubes and
mixed by vortex for 3 min to dissolve the residues. Finally, the
samples were subjected to centrifugation at 13,800 g for 5 min
at 4 °C, and then the supernatants (20 μl) were analyzed for
BUD content using the HPLC method. 
2.7.4. HPLC quantification assay 
The Chromaster HPLC system from Hitachi (Hitachi High-
Technologies Corporation, Tokyo, Japan), equipped with a
Hitachi 5410 UV-detector and Chromaster software, was used
for HPLC quantification of BUD. The applied method complied
with the procedure described in the USP41-NF36. The mobile
phase was a mixture of 32% (v/v) acetonitrile and 68%
(v/v) buffer (3.17 mg/ml monobasic sodium phosphate and
0.23 mg/ml phosphoric acid with a pH 3.2 ± 0.1) to elute
the samples at a flow speed of 1.5 ml/min through a column
(BDS Hypersil C 18 5.0 μm, 250 mm × 4.6 mm ID, Thermo Fisher
Scientific, USA). The column temperature was maintained at
40 °C and the detection wavelength was set at 254 nm. 20 μl of
samples were injected for each analysis. BUD quantification
was performed using a calibration curve of the peak area
versus drug concentration (10 to 2000 ng/ml), as described in
previous study [14] . Average recovery of BUD was from 98%
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Table 1 – BUD-specific input parameters for GastroPlus TM simulations. 
Parameter Value 
Molecular weight (g/mol) 430.54 a 
logD (pH 7.4) 2.42 a 
pK a (base) 13.74 a 
Permeability (rat jejunum) (cm/s) 1.41 × 10 −4 b 
Diffusion coefficient (cm 2 /s) 6.33 × 10 −7 c 
Dose (mg/kg body weight) 1.70 (intravenous bolus);1.92 (BUD-PT);2.23 (BUD-NC);1.84 (BUD-NEM) 
Mean precipitation time (s) 900.00 d 
Rat body weight (range) (g) 200.00–220.00 e 
Particle diameter ( μm) 2.32 (BUD-PT) e ;0.26 (BUD-NC) f ; 6.30 (BUD-NEM) f 
Blood/plasma concentration ratio 1.07 b 
Fraction unbound in plasma (%) 12.00 g 
Total clearance, Cl (l/h) 0.44 h 
Volume of distribution, Vd (l/kg) 0.37 h 
k 1/2 , k 2/1 (1/h) 30.12; 5.70 h 
k 1/3 , k 3/1 (1/h) 6.18; 0.10 h 
Pulmonary solubility (mg/ml) 0.05 (BUD-PT, BUD-NEM) a ;10.00 (BUD-NC) i 
k a (1/sec) 9.30 × 10 −3 ( BUD-PT, BUD-NC) i ;2.93 × 10 −3 (BUD-NEM) i 
Pulmonary permeability (cm/sec) 2.69 × 10 −6 (thoracic) c ;4.46 × 10 −6 (bronchiolar) c ; 1.57 × 10 −4 (alveolar) c 
a taken from Wu et al . [16] ; 
b calculated by GastroPlus TM integrated permeability converter based on Caco-2 cell permeability of 2.2 × 10 −5 cm/s (taken from Raje et al . 
[17] ); 
c GastroPlus TM calculated values; 
d GastroPlus TM default values; 
e experimentally determined; 
f taken from Liu et al . [14] ; 
g taken from Derendorf et al . [18] ; 
h PKPlus TM calculated values; 






















































o 102% with an RSD of inter-day and intra-day precision less 
han 2% in this range. LOD (limit of detection) and LOQ (limit 
f quantitation) were 20 ng/ml and 100 ng/ml, respectively. 
.8. In silico modeling of inhaled BUD formulations 
n silico modeling tools included MPPD model (version 3.04,
RA Inc, USA) and Gastroplus TM software (version 9.6,
imulation Plus Inc, USA). MPPD software was used to 
stimate BUD deposition in rat’s lungs, and the obtained 
ata were converted into GastroPlus TM identifiable values 
described in Supplementary data Appendix A). An add-in 
ulmonary Compartmental Absorption & Transit (PCAT TM ) 
odel in GastroPlus TM was used to predict drug absorption 
nd disposition following intratracheal administration of the 
ested formulations to rats. PCAT TM model was linked with 
dvanced Compartmental Absorption and Transit (ACAT) 
odel of the gastrointestinal (GI) tract to predict the 
bsorption of the swallowed drug fraction. 
Absorption of BUD following intratracheal administration 
o rats was modeled using the animal fasted-state ACAT 
odel, in conjunction with the PCAT TM model. The necessary 
nput parameters for GastroPlus TM simulations were 
btained from literature, in silico estimated or experimentally 
etermined in this study ( Table 1 ). Software default parameter 
alues for rat’s physiology in fasted state were used for the 
imulations. An add-in PKPlus TM module in GastroPlus TM 
oftware was used to estimate BUD pharmacokinetic 
arameters based on the obtained plasma concentration-time 
rofile following intravenous drug administration to rats. The stimated pharmacokinetic parameters were used to generate 
UD-specific model for intravenous bolus injection and 
ntratracheally administered formulations (BUD-PT, BUD-NC 
nd BUD-NEM). For the simulations regarding three inhalation 
ormulations, two types of drug deposition data were tested 
s inputs: (i) in vivo determined values obtained from the in 
ivo assesment of particle deposition of three inhaled BUD 
ormulations (D1), (ii) in silico predicted values (D2) based on in 
itro aerodynamic particle size data. In addition, dissolution 
f inhaled BUD in the lungs was predicted based on the mean 
eometric particle size data and pulmonary drug solubility 
sing software default Johnson dissolution equation. Default 
bsorption rate constant from pulmonary compartments 
k a ) was calculated using software integrated equation which 
akes into account lung volume, blood flow rate, tissue-plasma 
artition coefficient and blood-to-plasma concentration ratio.
ensitivity analysis, an additional software feature, was used 
o assess the influence of the selected input parameter values 
n the predicted drug absorption profile. For this purpose,
he selected input parameter value was gradually changed 
ithin a predefined range while keeping all other parameters 
t the baseline levels. The results are expressed as sensitivity 
oefficient (SC), calculated as: 
C = fractional change in output value 
fractional change in input value 
(1) 
The simulation results were compared with the in vivo 
esults in order to evaluate the designed BUD-specific model.
redictability of the generated model was assessed based 
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Table 2 – In vitro determined aerodynamic properties of 
BUD-PT and BUD-NEM (mean ± SD, n = 3). 
Formulation MMAD (μm) GSD 
BUD-PT 2.63 ± 0.11 1.97 ± 0.07 
BUD-NEM ∗ 5.33 ± 0.05 1.68 ± 0.02 



















































































on the fold error between the predicted and mean in vivo
observed data ( Eq. 2 ), considering that the prediction is better
if the fold error value is closer to 1. If the predicted value
ranged within two-fold of the observed value, the prediction
was considered acceptable [19–22] . In addition, coefficient of
determination (R 2 ) was calculated to assess linearity between
the simulated and observed values of drug pharmacokinetic
parameters: C max , T max and AUC 0 → ∞ . 
F old error = Predicted 
Observed 
(2)
3. Results and discussion 
3.1. Aerodynamic particle size of aerosolized BUD-PT and 
BUD-NEM 
The aerodynamic properties of BUD-NEM and BUD-PT are
depicted in Table 2 . The calculated MMAD and GSD of BUD-
PT from the NGI measurement were 2.63 ± 0.11 μm and 1.97 ±
0.07 μm, respectively. However, these values might not reflect
the aerodynamic properties of BUD-PT in the animal study.
This is because BUD-PT consisted of a mixture of micronized
BUD powder (Pulmicort R ©) and inhalation lactose that was
directly sprayed in the rat’s trachea. The dispersing pattern of
BUD-PT in the animal study is different from that being dosed
using a DPI device, where the micronized BUD particles could
disattach from the inhalation lactose due to the air turbulence
generated in the DPI device during inhalation. Therefore,
discrete deposition of micronized BUD and inhalation lactose
could be expected in human lungs but not in the animal lungs
in this study. In other words, most of the drug particles are
expected to stay attached to the lactose surface during passive
insufflation into rats’ trachea, and only the free fraction
of micronized BUD will reach deep lungs. This scenario is
elaborated in the Supplementary data Appendix B. 
3.2. Droplets size of aerosolized BUD-NC 
The droplet size of aerosolized BUD-NC was measured to
assess the aerodynamic properties of BUD-NC. This approach
differed from the one applied for the other two formulations
since BUD-NC was a liquid formulation and we could assume
that droplet size would be a better predictor of drug deposition
in the lungs than diameter of solid particles i.e., nanocrystals.
The droplet size data were found to be d 10 = 18.60 ± 1.17 μm,
d 50 = 27.90 ± 1.78 μm, d 90 = 43.23 ± 4.28 μm, and span = 0.89 ±
0.08. These values suggested that majority of aerosolized BUD-
NC was expected to deposit in the upper airway of the animal
lungs by inertia. Namely, considering the mode of BUD-NCdosing in the pharmacokinetic study, and the fact the BUD-
NC was aerosolized by the MicroSprayer TM within the animal
trachea tube, we postulated that majority of BUD-NC would
impact on the first branch of the bronchea, and less BUD-NC
would reach animal’s alveoli. 
3.3. In vivo pharmacokinetic data 
Fig. 1 . shows the plasma concentration-time course of
BUD intravenous injection, and BUD-PT, BUD-NC and BUD-
NEM following intratracheal administration to rats. BUD-PT
exhibited quick absorption and reached C max at ca . 5 min. BUD-
NC exhibited even faster absorption ( T max = 2 min), so it was
not possible to observe an absorption phase. Among the tested
formulations, BUD-NEM exhibited the slowest absorption rate
and concomitant drug entry to systemic circulation. 
3.4. In vivo and in silico pulmonary deposition 
The deposition patterns of BUD-PT, BUD-NC and BUD-NEM
in the animal lungs, obtained from the in vivo assessment
[15] are shown in Fig. 2 A , and denoted as D1. The lung
deposition of the investigated formulations (BUD-PT, BUD-NC
and BUD-NEM) in the animals predicted by MPPD is shown in
Fig. 2 B . In order to be used as inputs in the PCAT TM model
to determine drug absorption, these data (in particular, MPPD
generated drug deposition in tracheobronchial region) had to
be converted to the deposited drug fractions in thoracic and
bronchiolar regions, as shown in Fig. 2 C , and denoted as D2.
The conversion of data from Fig. 2 B to the data in Fig. 2 C is
explained in Supplementary data Appendix A. 
The in vivo results for the inhaled microparticles (BUD-
NEM) showed that the deposited drug fraction in alveoli
(61.00%) was much higher than the in silico estimated value
(3.29%). Such a difference can be explained by the fact that
current in silico pulmonary models are not able to simulate
mucoadhesion of BUD-NEM particles (composed of HA as
a mucoadhesive polymer), which has been demonstrated
in the in vitro study [14] . The difference between observed
(36.80%) and predicted (0.02%) fractions of drug deposited
in alveoli for the inhaled nanocrystals (BUD-NC) was also
pronounced, most likely because MPPD predictions were
based on the average droplet size (d 50 = 27.90 μm) while in
the in vivo environment these droplets might disperse due to
impaction (droplets were ejected using high speeds). In the
case of BUD-PT formulation, the predicted alveolar fraction
(4.88%) was also lower than the observed one (19.08%) but
the difference was not as pronounced as in the case of
other two formulations. In order to estimate the prediction
power of the in silico generated (D2) vs the in vivo determined
drug deposition data (D1), both sets of data were used as
inputs for BUD absorption simulations. In addition, we have
tested the alternative scenarios based on the more realistic
assessment of insufflated BUD-PT aerodynamic performance
(Supplementary data Appendix B). 
3.5. In silico model construction 
In order to generate an in silico drug-specific absorption model,
input data have to be carefully selected and justified. However,
356 Asian Journal of Pharmaceutical Sciences 16 (2021) 350–362 
Fig. 1 – Plasma concentration-time profiles for intravenously and intratracheally administered BUD formulations (mean ±
SD, n = 5). The insert shows the zoomed region of 0–4 h. 
Fig. 2 – Pulmonary deposition data for formulations BUD-PT, BUD-NC and BUD-NEM: in vivo determined (D1 deposition) (A), 
















Fig. 3 – Predicted and observed mean plasma 
concentration-time profiles following 1.70 mg/kg BUD 
intravenous bolus administration in rats. ome parameter values may be associated with certain 
evel of uncertainty. PKPlus TM analysis of the intravenous 
ata indicated that BUD pharmacokinetics in rats can be 
escribed by three-compartmental model. The calculated 
harmacokinetic parameters are provided in Table 1 . 
Simulations results for BUD intravenous bolus 
dministration in rats are shown on Fig. 3 , along with 
he in vivo observed values. It can be noted that the course 
f the predicted plasma concentration-time profile is in good 
greement with the observed data. However, the predicted 
 0 (4505.30 ng/ml) was more than four times higher than 
he observed C 0 (1012.40 ng/ml). This discrepancy may be 
xplained by the late first sampling time in the in vivo 
xperiment. Namely, it is likely that the real C 0 was missed 
ecause e.g., first sampling could not be performed quickly 
nough to capture the real C 0 value. 
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Fig. 4 – Intratracheal administration of BUD-PT (1.92 mg/kg BUD): predicted and observed mean BUD plasma 
concentration-time profiles (A); comparison of the observed and predicted pharmacokinetic parameters: C max1 , T max1 , C max2 , 
T max2 and AUC 0 → ∞ (markers) where lines represent two-fold error for the observed pharmacokinetic parameters based on 

















































3.6. In silico model exploration 
3.6.1. Formulation (i) BUD-PT 
Based on the same input dataset as for intravenous bolus
injection, and using the additional input parameters to
describe drug performance in the pulmonary compartments
( Table 1 ), the generated model was used to predict BUD
absorption following intratracheal administration of BUD-PT
to rats. Pulmicort R © performance in humans have already
been addressed in literature [16 ,23–25] , but deposition data for
intratracheally administered BUD in rats are lacking, and BUD
pharmacokinetic data in rats are rather scarce [14 ,26] . 
Fig. 4 A shows the simulated BUD plasma concentration-
time profiles following intratracheal administration of BUD-
PT using two different deposition inputs (D1 and D2).
The predicted pharmacokinetic parameters are provided in
Table 3 . In both cases, the simulations indicated two peaks
in the pharmacokinetic profiles. These two peaks are also
visible in the mean in vivo observed profile. The first peak
represents BUD absorption from the lungs, while the second
peak signifies drug absorption from the gastrointestinal (GI)
tract. Such performance can be explained by pulmonary drug
deposition i.e., high fraction of drug dose deposited in the
upper parts of the respiratory tract ( Fig. 2 ), which will be
cleared by mucociliary clearance, and eventually swallowed. 
Another observation considering BUD-PT is that D1
deposition input resulted in better prediction of the in vivo
determined mean plasma profile, as illustrated by higherR 2 value ( Fig. 4 B and 4 C ). However, both profiles simulated
based on D1 and D2 deposition inputs provided reasonable
prediction of the actual in vivo profile since the error between
the predicted and observed pharmacokinetic parameters was
less than two folds ( Table 3 , Fig. 4 B and 4 C ). In addition,
regional drug absorption patterns from the lungs were similar
for D1 and D2 deposition inputs ( Fig. 4 D ). This finding signifies
that, in the case of non-mucoadhesive inhalation powders,
certain differences between in vivo determined and in silico
predicted drug deposition profiles in the lungs would not
notably impair the prediction power of the in silico drug
absorption simulations. In other words, the results suggest
that, if the in vivo deposition data are lacking, in vitro
aerodynamic assessment of non-adhesive inhalation powders
may suffice in providing inputs for reasonably good prediction
of drug absorption profile. 
3.6.2. Formulation (ii) BUD-NC 
In the next step, BUD-specific in silico model was used
to simulate drug absorption following intratracheal
administration of BUD-NC. As in the case of BUD-PT, the
predictions of BUD absorption from BUD-NC were performed
for two different deposition data inputs (D1 and D2). The
simulation results based on different solubility inputs
( Fig. 5 A and Table 4 ) clearly demonstrate that BUD pulmonary
solubility is one of the key factors affecting its absorption.
Namely, under the assumption that BUD dissolution in
the lungs is governed by the input solubility (0.05 mg/ml),
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Table 3 – Predicted and observed pharmacokinetic parameters for BUD-PT (1.92 mg/kg BUD). 
Parameter Observed Predicted (D1) Fold error Predicted (D2) Fold error 
C max1 ∗ (ng/ml) 132.70 128.05 0.96 91.25 0.69 
T max1 ∗ (h) 0.25 0.16 0.64 0.08 0.32 
C max2 ∗∗ (ng/ml) 98.35 112.13 1.14 115.92 1.17 
T max2 ∗∗ (h) 2.00 2.16 1.08 2.56 1.28 
AUC 0 → ∞ (ng • h/ml) 985.73 949.63 0.96 949.52 0.96 
∗ corresponds to the first peak; 
∗∗ corresponds to the second peak. 
Table 4 – Predicted and observed pharmacokinetic parameters for formulation BUD-NC (2.23 mg/kg BUD). 
Parameter Observed Predicted (D1) Fold error Predicted (D2) Fold error 
Cs (mg/ml) 0.05 10 10 0.05 10 10 
C max (ng/ml) 1022.10 209.95 848.91 0.83 141.75 1021.40 0.99 
T max (h) 0.03 0.40 0.03 1.00 2.80 0.08 2.66 
AUC 0 → ∞ 
(ng ·h/ml) 




































































eak drug absorption from BUD-NC formulation (profiles 
Predicted, Cs (pulm) 0.05 mg/ml (D1)" and "Predicted, Cs 
pulm) 0.05 mg/ml (D2)" in Fig. 5 A ) would be much lower than
bserved in vivo . 
To explain the reasons for rapid drug absorption following 
ntratracheal aerosolization of formulation BUD-NC, we 
ssumed that BUD in vivo dissolution from the nebulized 
anosuspension formulation is faster and more complete 
han expected based on the initial input solubility value,
ost likely because of the nanosize effect on drug particle 
issolution and the presence of additional water (to dissolve 
he drug) in the nebulized droplets. This hypothesis has also 
een supported by Yang et al . [26] who commented that 
UD nanosuspension (with average particle diameter less 
han 0.5 μm) behaved more like solution than conventional 
uspension. Also, Yang et al . [26] annotated that high BUD 
ermeability across lung epithelial cells, along with the lack of 
ajor first pass metabolism, contributed to rapid absorption 
f the aerosolized drug. In addition, it has been annotated in 
iterature that nanocrystals/nanoparticles possess increased 
urface to volume ratio in comparison to larger particles 
 i.e., microparticles), which leads to notable increase in drug 
issolution rate and saturation solubility [27–32] . To simulate 
nhanced BUD dissolution from BUD-NC nanosuspension,
nd a scenario where drug solubility and dissolution are not 
imiting factors for drug absorption, pulmonary drug solubility 
as increased to 10 mg/ml. In addition, the model assumed 
ast drug absorption from pulmonary compartments, as 
eflected in the high absorption rate constant ( Table 1 ). The 
redicted plasma concentration-time profiles based on the 
ptimized input value for pulmonary drug solubility (profiles 
Predicted, Cs (pulm) 10 mg/ml (D1)" and "Predicted, Cs (pulm) 
0 mg/ml (D2)" in Fig. 5 A ) matched the in vivo observed profile 
ell. As visible in Fig. 5 A , these two plasma concentration- 
ime profiles partially overlap. Fig. 5 A and Table 4 illustrate the differences in 
he estimated BUD absorption from formulation BUD- 
C, depending on the input deposition data and drug 
olubility value. The differences between the predicted 
harmacokinetic parameters based on D1 and D2 deposition 
nputs were pronounced solely in the case when drug 
olubility was the limiting factor for dissolution (initial 
olubility of 0.05 mg/ml), and were caused by the differences 
n the fraction of drug deposited in alveolar region. Higher 
raction of drug deposited in alveoli in the case of D1 
eposition led to faster drug absorption ( Table 4 ). On the 
ther hand, simulations based on the assumption that BUD 
olubility from a nebulized suspension would not impair 
article dissolution and absorption (solubility of 10 mg/ml) 
emonstrate that both D1 and D2 deposition inputs yield 
imilar prediction outcomes ( Table 4 ). In both cases, the 
imulated pharmacokinetic parameters were within two-fold 
rror of the mean observed data, except T max predicted based 
n D2 deposition ( Table 4 , Fig. 5 B and 5 C ). Although not visible
n the drug plasma concentration profiles, the only difference 
ere lies in the pulmonary regional drug absorption ( i.e., the 
ighest fraction of inhaled drug in the case of D1 deposition 
as absorbed from alveoli, while in the case of D2 deposition 
he drug was predominantly absorbed from bronchiolar 
egion), as illustrated in Fig. 5 D . 
Overall, modeling results demonstrated that increasing 
rug solubility was the essential step to obtain meaningful 
rediction results for BUD-NC. In other words, data for 
he formulation BUD-NC revealed that pulmonary solubility 
f a highly permeable drug is the key factor affecting its 
ulmonary absorption from the nanosuspension, and if the 
olubility of such particles is high enough, the type of 
eposition data ( in vivo vs . in silico ) would not influence the
imulation results in terms of drug plasma concentration 
rofile ( Fig. 5 A ). However, accurate particle deposition profile 
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Fig. 5 – Intratracheal administration of BUD-NC (2.23 mg/kg BUD): predicted and observed BUD mean plasma 
concentration-time profiles (A); comparison of the observed and predicted pharmacokinetic parameters: C max , T max and 
AUC 0 → ∞ (markers) assuming drug solubility of 10 mg/ml where lines represent two-fold error for the observed 
pharmacokinetic parameters: based on D1 deposition data (B); based on D2 deposition data (C); predicted BUD regional 






























is important for the prediction of regional drug absorption
from the lungs ( Fig. 5 D ). 
3.6.3. Formulation (iii) BUD-NEM 
An additional challenge in exploring the generated BUD-
specific absorption model referred to the simulation of drug
absorption following intratracheal administration of BUD-
NEM. The in vivo results ( Fig. 1 ) for BUD-NEM demonstrated
delayed drug absorption. According to Liu et al . [14] ,
such performance can be attributed to the pronounced
mucoadhesion of HA microparticles, and consequently,
prolonged drug retention in the lungs. 
In silico simulation of delayed drug absorption was difficult
because the software built-in PCAT TM model is not able to
simulate prolonged particle mucoadhesion, and prolonged
drug retention and dissolution in the lungs. Namely, the
current version of the PCAT TM model does not offer the optionto use drug pulmonary retention time and dissolution data as
inputs for the simulations. Therefore, an alternative approach
of changing drug absorption rate constant (k a ) was applied,
which has been proved by Bhagwat et al . [33] . Sensitivity of
the predicted pharmacokinetic parameters to the input k a
values was first tested using Sensitivity Analysis, and the
obtained data indicate marked influence of this parameter on
drug absorption from BUD-NEM formulation ( e.g., sensitivity
analysis for alveolar k a resulted in SC = 0.73 for C max and
SC = -3.37 for T max ). It should be noted here that a parameter
is classified as having a high influence on the output value if
SC ≥ 0.5 [34] . In order to illustrate the effect of k a , we’ve tested
three different scenarios referring to different k a values (noted
in Table 5 ). 
Fig. 6 A and Table 5 illustrate the effect of different k a values
on the predicted BUD plasma profile following intratracheal
administration of formulation BUD-NEM, assuming the in
360 Asian Journal of Pharmaceutical Sciences 16 (2021) 350–362 
Table 5 – The influence of different k a values on the predicted pharmacokinetic parameters for formulation BUD-NEM 
(1.84 mg/kg BUD). 
Parameter Observed Predicted k a = 9.30 × 10 −3 1/sec Predicted k a = 2.93 × 10 −3 1/sec Predicted k a = 9.30 × 10 −4 1/sec 
D1 D2 D1 D2 D1 D2 
C max (ng/ml) 206.43 223.49 113.98 157.29 110.68 87.82 104.56 
T max (h) 2.00 0.64 2.56 1.84 2.88 2.88 3.04 
AUC 0 → ∞ 
(ng ·h/ml) 
864.60 883.40 881.54 883.27 881.31 883.07 881.00 
Fig. 6 – Intratracheal administration of BUD-NEM (1.84 mg/kg BUD): the influence of different k a values on the predicted BUD 
plasma concentration-time profiles based on D1 deposition data (A); based on D2 deposition data (B); comparison of the 
observed and predicted (based on k a of 2.93 × 10 −3 1/sec) pharmacokinetic parameters: C max , T max and AUC 0 → ∞ (markers) 
where lines represent two-fold error for the observed pharmacokinetic parameters based on D1 deposition data (C); based 







































ivo determined (D1) input deposition data. The initial k a 
alue (9.30 × 10 −3 1/sec), representing fast drug absorption,
esulted in relatively good prediction of BUD C max and AUC 0 → ∞ 
ollowing administration of BUD-NEM, but the predicted 
ate of drug absorption in terms of T max (0.64 h) deviated 
rom the mean in vivo observed value (2.00 h). On the other 
and, when ten times decreased k a value (9.30 × 10 −4 1/s) 
as tested as input, the resulting C max was much lower 
han the mean in vivo value, and the predicted time to 
eak plasma concentration (2.88 h) exceeded the in vivo 
bserved T max . Only the predicted AUC 0 → ∞ stayed relatively 
naffected, regardless of the input k a . The optimal input 
 a value, that resulted in the best matching between the 
redicted and mean observed pharmacokinetic parameters,
as 2.93 × 10 −3 1/s. The predicted C max based on this k a , was 
ower than the mean observed value, but fitted into the range 
f individually observed values (121.95–360.70 ng ·h/ml). In 
ddition, the shape of the predicted plasma concentration- 
ime curve matched the observed profile well ( Fig. 6 and 
able 5 ). The prediction results based on the in silico estimated drug 
eposition (D2) and different input k a values are provided 
n Fig. 6 B and Table 5 . It can be seen that the influence
f different input k a values on the predicted drug plasma 
rofiles is not that pronounced as in the case of D1 deposition,
robably because the fraction of drug deposited and absorbed 
rom alveoli is much lower than for D1 deposition. 
The obtained data, based on the optimized k a value 
2.93 × 10 −3 1/s), indicate that the in vivo determined BUD- 
EM deposition in the lungs (D1) provided better prediction 
f BUD in vivo plasma profile in comparison to the in silico 
stimated D2 deposition ( Table 6 ). These results imply that in 
ilico (MPPD) modeling may not accurately predict pulmonary 
rug deposition in rats, and if possible, it is preferable to 
se in vivo determined drug deposition data to predict the 
xpected drug absorption profile. In other words, for this 
ind of formulations, in vivo animal deposition studies are 
eeded. This is also evident in Fig. 6 C and 6 D showing that
ll the pharmacokinetic parameters, predicted based on D1 
eposition and the optimized k a (2.93 × 10 −3 1/s), were within 
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Table 6 – Predicted (based on k a of 2.93 × 10 −3 1/sec) and observed pharmacokinetic parameters for formulation BUD-NEM 
(1.84 mg/kg budesonide). 
Parameter Observed Predicted (D1) Fold error Predicted (D2) Fold error 
C max (ng/ml) 206.43 157.29 0.76 110.68 0.54 
t max (h) 2.00 1.84 0.92 2.88 1.44 







































































two-fold error of the mean observed data, while the predicted
C max corresponding to D2 deposition lied on the borderline.
Consequently, the calculated R 2 between the observed and
predicted values was higher for the prediction based on D1
deposition ( Fig. 6 C and 6 D ). 
The prediction results (based on the optimized k a value
of 2.93 × 10 −3 1/s) showing regional lung distribution of BUD
absorption following intratracheal administration of BUD-
NEM in rats are depicted in Fig. 6 E . It can be observed that
the fraction of BUD absorbed from alveoli in the case of D1
deposition is higher than in the case of D2 deposition. This
can be explained by the pronounced differences in fractions
of the drug deposited in alveoli between D1 and D2 deposition
( Fig. 2 ). 
Overall, in silico modeling results indicate that prediction
of drug absorption pattern following administration of
an inhaled formulations with pronounced mucoadhesive
properties is rather challenging due to difficulties in
determining drug absorption rate constant from the lung
compartments. The approach applied in this study, based on
the optimization of k a value, can be used for rough predictions
of pulmonary drug absorption when drug plasma exposure
data are available to validate the simulation data. However,
such an approach is not applicable in the early phases of
formulation development, before conduction the in vivo
pharmacokinetic studies. 
4. Conclusion 
In this study, we tested the value of in vitro-in vivo-in silico
approach using inhaled BUD formulations in a rat model, and
highlighted the importance of input parameters to predict
the expected drug pharmacokinetic outcome. Our findings
include the following: 
(i) In vitro-in silico predicted pulmonary drug deposition
might serve as a suitable alternative to predict drug absorption
following inhalation of relatively simple formulations such
as non-mucoadhesive nanosuspensions or dry powders for
inhalation. Considering that in vivo drug particle deposition
studies are laborious and time-consuming, a simplified in
vitro-in silico approach may facilitate the development of
new inhaled formulations in a competitive pharmaceutical
industry environment. (ii) The in vitro-in vivo-in silico approach
used in this study was found helpful in determining
the absorption patterns of inhaled BUD formulations with
different biopharmaceutical properties. Since determination
of fraction of drug absorbed through the lungs is an
important issue in the development of inhaled formulations,
the proposed approach may facilitate the decision on thepromising formulation in terms of providing the desired drug
absorption profile. (iii) Moreover, in silico modeling enabled
to elucidate the differences in drug regional absorption
distribution in the lungs depending on particle deposition
data, even in cases when differences in drug pulmonary
deposition were not reflected in the estimated drug plasma
concentration profiles ( i.e., as in the case of BUD-NC
formulation). Such mechanistic analysis, which cannot be
determined in vivo , is highly important in the development
of inhaled formulations for targeted drug delivery/absorption
in a particular lung compartment. (iv) In silico tools need
to be improved in order to better simulate drug absorption
profile following administration of inhaled formulations e.g.,
by allowing the input of drug retention time in the lung
( e.g., prolonged drug retention due to mucoadhesion) along
with drug release rate obtained under biorelevant in vitro
conditions. 
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